| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H14ClN3O6 |
| Molecular Weight | 367.741 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCC(=O)NC1=CC(=CC(NC(=O)COC(C)=O)=C1Cl)C#N
InChI
InChIKey=VNVBCWREJHKWSG-UHFFFAOYSA-N
InChI=1S/C15H14ClN3O6/c1-8(20)24-6-13(22)18-11-3-10(5-17)4-12(15(11)16)19-14(23)7-25-9(2)21/h3-4H,6-7H2,1-2H3,(H,18,22)(H,19,23)
| Molecular Formula | C15H14ClN3O6 |
| Molecular Weight | 367.741 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Histamine release was enhanced by the pretreatment of basophils with recombinant interleukin 3 (rIL-3) (0.3-10 U/ml) in 18 out of 22 subjects. Histamine release in the presence of rIL-3 was inhibited by TYB-2285 (ACREOZAST) in a dose-dependent manner (1-100 microM). Histamine release in the absence of rIL-3 was not inhibited by TYB-2285 at concentrations less than 1 mM.
